GLP-1 drugs and osteoarthritis risk in diabetes
Treatments studied
Part of Bones, joints & muscles clinical trials.
This study looks at whether GLP-1 analog medications (a type of diabetes drug) can lower the risk of developing osteoarthritis in people with type 2 diabetes. It compares them to another diabetes drug class, SGLT2 inhibitors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older.
- You have type 2 diabetes (not type 1).
- You have been taking either an SGLT2 inhibitor or a GLP-1 analog for at least one year.
- You are not taking mealtime (prandial) insulin.
- You do not have a condition like rheumatoid arthritis, an autoimmune disease, or use certain medications like corticosteroids or TNF blockers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
This study tests whether a diabetes medication called a GLP-1 receptor agonist can help improve bone and muscle health in older women with type 2 diabetes who are at risk for osteoporosis. It aims to see if the drug can strengthen bones and prevent falls.
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.
This study tests if a type 2 diabetes medication called a GLP-1 receptor agonist (like Ozempic) is safe and effective for people on dialysis. It may help manage blood sugar and improve health outcomes for those with kidney failure.
This study tests whether a GLP-1 medication (like Ozempic) can help people with obesity who are having hip or knee replacement surgery. It aims to see if the medication improves recovery and outcomes.
Hear when a new Osteoarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.